BACKGROUND: Improved endothelial function may contribute to the beneficial effects of cholesterol-lowering therapy. METHODS AND RESULTS: In this randomized, double-blind study, we compared the effect of 6 months of simvastatin (40 mg/d) treatment with that of placebo on coronary endothelial vasomotor function in 60 patients with coronary artery disease. Simvastatin lowered LDL-cholesterol by 40+/-12% from 130+/-28 mg/dL (P<0.001). Peak intracoronary acetylcholine infusion produced epicardial coronary constriction at baseline in both the simvastatin (-17+/-13%) and placebo (-24+/-16%) groups. After treatment, acetylcholine produced less constriction in both groups (-12+/-19% and -15+/-14%, respectively, P=0.97). The increase in coronary blood flow during infusion of the peak dose of substance P was blunted at baseline in both the simvastatin (42+/-50%) and placebo (55+/-71%) groups, reflecting impaired endothelium-dependent dilation of coronary microvessels. After treatment, the flow increase was 82+/-81% in the simvastatin group and 63+/-53% in the placebo group (P=0.16). CONCLUSIONS: Six months of cholesterol-lowering therapy has no significant effect on coronary endothelial vasomotor function in the study population of patients with coronary artery disease and mildly elevated cholesterol levels. These findings suggest that the effects of cholesterol lowering on endothelial function are more complex than previously thought.
RCT Entities:
BACKGROUND: Improved endothelial function may contribute to the beneficial effects of cholesterol-lowering therapy. METHODS AND RESULTS: In this randomized, double-blind study, we compared the effect of 6 months of simvastatin (40 mg/d) treatment with that of placebo on coronary endothelial vasomotor function in 60 patients with coronary artery disease. Simvastatin lowered LDL-cholesterol by 40+/-12% from 130+/-28 mg/dL (P<0.001). Peak intracoronary acetylcholine infusion produced epicardial coronary constriction at baseline in both the simvastatin (-17+/-13%) and placebo (-24+/-16%) groups. After treatment, acetylcholine produced less constriction in both groups (-12+/-19% and -15+/-14%, respectively, P=0.97). The increase in coronary blood flow during infusion of the peak dose of substance P was blunted at baseline in both the simvastatin (42+/-50%) and placebo (55+/-71%) groups, reflecting impaired endothelium-dependent dilation of coronary microvessels. After treatment, the flow increase was 82+/-81% in the simvastatin group and 63+/-53% in the placebo group (P=0.16). CONCLUSIONS: Six months of cholesterol-lowering therapy has no significant effect on coronary endothelial vasomotor function in the study population of patients with coronary artery disease and mildly elevated cholesterol levels. These findings suggest that the effects of cholesterol lowering on endothelial function are more complex than previously thought.
Authors: H J Mulder; M J Schalij; B Kauer; R F Visser; P R van Dijkman; J W Jukema; A H Zwinderman; A V Bruschke Journal: Heart Date: 2001-11 Impact factor: 5.994
Authors: Andreas J Flammer; Todd Anderson; David S Celermajer; Mark A Creager; John Deanfield; Peter Ganz; Naomi M Hamburg; Thomas F Lüscher; Michael Shechter; Stefano Taddei; Joseph A Vita; Amir Lerman Journal: Circulation Date: 2012-08-07 Impact factor: 29.690
Authors: Markus Ferrari; Gerald S Werner; Barbara M Richartz; Albrecht Oehme; Eberhard Straube; Hans R Figulla Journal: Cardiovasc Ultrasound Date: 2005-04-27 Impact factor: 2.062
Authors: Thomas Felix Lüscher; Michael Pieper; Michael Tendera; Mathy Vrolix; Wolfgang Rutsch; Frank van den Branden; Robert Gil; Karl-Otto Bischoff; Michael Haude; Dieter Fischer; Thomas Meinertz; Thomas Münzel Journal: Eur Heart J Date: 2009-05-27 Impact factor: 29.983